Xinnate is developing pharmaceutical therapies based on a pioneering technology of immune modulating peptides, that targets dysfunctional healing by controlling presence of microbes and the complex interplay of inflammatory responses.

Xinnate is conducting an ambitious research and clinical program for TCP-25, which includes a phase 1b clinical study in patients with Epidermolysis Bullosa (EB). Late-stage clinical development and commercialization will take place in partnership with one or more leading pharmaceutical companies.